Malignant Tumors clinical trials

Explore recruiting malignant tumors clinical trials.

Recruiting malignant tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Italy, France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Mesalamine for colorectal cancer prevention program in Lynch syndrome

Sweden, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study

Portugal, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

France, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

Spain, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Dose Finding and Phase 2 Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Malignant Tumors trials by city

Malignant Tumors in Toronto Malignant Tumors in Vancouver Malignant Tumors in Montreal Malignant Tumors in Calgary Malignant Tumors in Edmonton Malignant Tumors in Ottawa Malignant Tumors in Winnipeg Malignant Tumors in Quebec City Malignant Tumors in Hamilton Malignant Tumors in Kitchener Malignant Tumors in London Malignant Tumors in Halifax Malignant Tumors in New York Malignant Tumors in Los Angeles Malignant Tumors in Chicago Malignant Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease